• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BioNTech SE - American Depositary Shares (NQ:BNTX)

    89.91 +2.12 (+2.41%)
    Streaming Delayed Price Updated: 11:08 AM EDT, May 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about BioNTech SE - American Depositary Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    72 73 Next >
    News headline image
    BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM ↗
    BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a... 
    Via MarketBeat
    News headline image
    3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
    Investors can find much better opportunities. 
    Via The Motley Fool
    BioNTech Q1 2026 Revenue Miss Overshadows Pipeline Progress as NASDAQ:BNTX Slides ↗
    Via Chartmill
    BioNTech SE (NASDAQ:BNTX) Stock Plummets 17% on Q4 Loss and Co-Founders' Planned Exit ↗
    Via Chartmill
    News headline image
    Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors. ↗
    This may be an excellent deal for those focused on the long game. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    BioNTech Announces New ADS Repurchase Program
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech Announces First Quarter 2026 Financial Results and Corporate Update
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    2 Healthcare Stocks to Buy and 1 to Approach With Caution ↗
    Recent performances don't tell the whole story. 
    Via The Motley Fool
    News headline image
    BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
    As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the... 
    Via Finterra
    Topics Initial Public Offering
    News headline image
    BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery
    The biotech sector has found its new North Star in 2026. As of mid-March, Moderna Inc. (NASDAQ: MRNA) has shocked Wall Street with a staggering 83% year-to-date gain, catapulting it to the upper... 
    Via MarketMinute
    Topics Artificial Intelligence Initial Public Offering Stocks
    News headline image
    Why BioNTech Stock Is Getting Crushed Today ↗
    Nothing about the recent past, present, or foreseeable future seems all that compelling. 
    Via The Motley Fool
    Gapping stocks in Tuesday's session ↗
    Via Chartmill
    News headline image
    BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier
    In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the... 
    Via MarketMinute
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Why Did BNTX Stock Tumble 17% Pre-Market Today? ↗
    BioNTech co-founders Ugur Sahin and Özlem Türeci are set to leave the company to head the new venture. 
    Via Stocktwits
    News headline image
    BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology
    On March 6, 2026, Moderna, Inc. (NASDAQ: MRNA) remains the centerpiece of biotech conversations following a staggering 14% surge in its share price earlier this week. For a company that became a... 
    Via Finterra
    Topics Initial Public Offering Intellectual Property
    News headline image
    Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement
    In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant... 
    Via MarketMinute
    Topics Intellectual Property Lawsuit
    News headline image
    Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era
    Today’s Date: March 5, 2026 Introduction The narrative surrounding Moderna, Inc. (NASDAQ: MRNA) shifted dramatically this morning as the biotechnology pioneer’s shares surged 15.99%, reclaiming a level... 
    Via Finterra
    Topics Intellectual Property
    News headline image
    BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot
    As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a... 
    Via MarketMinute
    Topics Artificial Intelligence Economy Initial Public Offering
    News headline image
    Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
    As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based... 
    Via Finterra
    Topics Economy Intellectual Property
    News headline image
    Moderna (MRNA) Deep Dive: Navigating Regulatory Blows and the Pivot to Oncology
    Today, February 11, 2026, marks a volatile chapter for Moderna, Inc. (NASDAQ: MRNA). The biotechnology pioneer, which became a household name during the COVID-19 pandemic, finds itself at a critical... 
    Via Finterra
    Topics Artificial Intelligence Initial Public Offering Intellectual Property
    News headline image
    BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    2 Biotech Stocks Set to Rebound in 2026 ↗
    They could perhaps see sustained runs beyond this year. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    72 73 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.